Vitamin D signaling in intestinal innate immunity and homeostasis

Molecular and Cellular Endocrinology

Volumn 453, Issue , 2017, Pages 68-78

  Dimitrov, Vassil ^a   White, John H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Barrier function; Gut homeostasis; Inflammatory bowel disease; Innate immunity; Microbiome; Vitamin D

Indexed keywords

25 HYDROXYERGOCALCIFEROL; BETA DEFENSIN 2; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHOLESTANETRIOL 26 MONOOXYGENASE; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 22; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRILYSIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PATTERN RECOGNITION RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; VITAMIN D; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; CALCIUM ABSORPTION; CATALYSIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HUMAN; HYDROXYLATION; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; INTESTINE TISSUE; LIFESTYLE; MACROPHAGE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALABSORPTION; MICROBIOME; MICROFLORA; NONHUMAN; OZONE LAYER; PANETH CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; ULTRAVIOLET B RADIATION; UPREGULATION; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; GASTROINTESTINAL TRACT; HOMEOSTASIS; IMMUNOLOGY; INTESTINE; INTESTINE FLORA; METABOLISM; MICROBIOLOGY;

ADAPTIVE IMMUNITY; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTESTINES; VITAMIN D;

EID: 85017425007     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2017.04.010     Document Type: Review

References (213)

1. Adams, J.S., Hewison, M., Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 4:2 (2008), 80–90.
2. Adams, J.S., et al. Regulation of the extrarenal CYP27B1-hydroxylase. J. Steroid Biochem. Mol. Biol. 144:Pt A (2014), 22–27.
3. Aiba, I., et al. Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids 71:10 (2006), 849–856.
4. Al Mutair, A.N., Nasrat, G.H., Russell, D.W., Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. J. Clin. Endocrinol. Metab. 97:10 (2012), E2022–E2025.
5. Al-Jaderi, Z., Maghazachi, A.A., Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins (Basel) 5:11 (2013), 1932–1947.
6. Ananthakrishnan, A.N., et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 142:3 (2012), 482–489.
7. Ananthakrishnan, A.N., et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm. Bowel Dis. 19:9 (2013), 1921–1927.
8. Ananthakrishnan, A.N., et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 12:5 (2014), 821–827.
9. Andjelkovic, Z., et al. Disease modifying and immunomodulatory effects of high dose 1α(OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatology 17:4 (1999), 453–456.
10. Arabi, A., El Rassi, R., El-Hajj Fuleihan, G., Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat. Rev. Endocrinol. 6:10 (2010), 550–561.
11. Ardalan, M.R., et al. Calcitriol started in the donor, expands the population of CD4+CD25+ T cells in renal transplant recipients. Transpl. Proc. 39:4 (2007), 951–953.
12. Assa, A., et al. Vitamin D deficiency predisposes to adherent-invasive Escherichia coli-induced barrier dysfunction and experimental colonic injury. Inflamm. Bowel Dis. 21:2 (2015), 297–306.
13. Balogh, G., et al. Effect of 1,25(OH)(2)-vitamin D(3) on the activation of natural killer cells: role of protein kinase C and extracellular calcium. Exp. Mol. Pathol. 67:2 (1999), 63–74.
14. Barbachano, A., et al. The endocrine vitamin D system in the gut. Mol. Cell Endocrinol. 453 (2017), 79–87.
15. Barrett, J.C., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40:8 (2008), 955–962.
16. Bartels, L.E., et al. 25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn's disease. Inflammopharmacology 21:2 (2013), 177–186.
17. Beaugerie, L., Itzkowitz, S.H., Cancers complicating inflammatory bowel disease. N. Engl. J. Med. 372:15 (2015), 1441–1452.
18. Benchimol, E.I., et al. Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflamm. Bowel Dis. 20:10 (2014), 1761–1769.
19. Bikle, D.D., Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 21:3 (2014), 319–329.
20. Bikle, D.D., et al. Differential regulation of epidermal function by VDR coactivators. J. Steroid Biochem. Mol. Biol. 121:1–2 (2010), 308–313.
21. BOLAND, R., Role of vitamin D in skeletal muscle function. Endocr. Rev. 7:4 (1986), 434–448.
22. Bostick, R.M., Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. J. Steroid Biochem. Mol. Biol. 148 (2015), 86–95.
23. Campbell, E.L., Colgan, S.P., Neutrophils and inflammatory metabolism in antimicrobial functions of the mucosa. J. Leukoc. Biol. 98:4 (2015), 517–522.
24. Cantorna, M.T., Waddell, A., The vitamin D receptor turns off chronically activated T cells. Ann. N. Y. Acad. Sci. 1317 (2014), 70–75.
25. Cantorna, M.T., Zhao, J., Yang, L., Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc. Nutr. Soc. 71:1 (2012), 62–66.
26. Chen, L., et al. Toll-like receptor 4 has an essential role in early skin wound healing. J. Invest. Dermatol 133:1 (2013), 258–267.
27. Chen, J., Bruce, D., Cantorna, M.T., Vitamin D receptor expression controls proliferation of naive CD8+ T cells and development of CD8 mediated gastrointestinal inflammation. BMC Immunol., 15, 2014, 6.
28. Chen, Y., et al. MicroRNA-346 mediates tumor necrosis factor alpha-induced downregulation of gut epithelial vitamin D receptor in inflammatory bowel diseases. Inflamm. Bowel Dis. 20:11 (2014), 1910–1918.
29. Chen, J., et al. Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to Citrobacter rodentium through modulation of innate lymphoid cells. Mucosal Immunol. 8:3 (2015), 618–626.
30. Cheng, J.B., et al. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J. Biol. Chem. 278:39 (2003), 38084–38093.
31. Cheng, J.B., et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. U. S. A. 101:20 (2004), 7711–7715.
32. Christakos, S., et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev. 96:1 (2016), 365–408.
33. Ciubotaru, I., et al. Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Transl. Res. 166:5 (2015), 401–411.
34. Colgan, S.P., Neutrophils and inflammatory resolution in the mucosa. Semin. Immunol. 27:3 (2015), 177–183.
35. Consortium, H.M.P, Structure, function and diversity of the healthy human microbiome. Nature 486:7402 (2012), 207–214.
36. Coombes, J.L., Powrie, F., Dendritic cells in intestinal immune regulation. Nat. Rev. Immunol. 8:6 (2008), 435–446.
37. Cooney, R., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 16:1 (2010), 90–97.
38. Coulombe, F., Behr, M.A., Crohn's disease as an immune deficiency?. Lancet 374:9692 (2009), 769–770.
39. Dimitrov, V., White, J.H., Species-specific regulation of innate immunity by vitamin D signaling. J. Steroid Biochem. Mol. Biol. 164 (2016), 246–253.
40. Dimitrov, V., et al. Non-classical mechanisms of transcriptional regulation by the vitamin D receptor: insights into calcium homeostasis, immune system regulation and cancer chemoprevention. J. Steroid Biochem. Mol. Biol. 144:Pt A (2014), 74–80.
41. Dougherty, U., et al. The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer. Clin. Cancer Res. 20:22 (2014), 5848–5859.
42. Du, J., et al. 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. Inflamm. Bowel Dis. 21:11 (2015), 2495–2506.
43. Ekbom, A., et al. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323:18 (1990), 1228–1233.
44. El-Matary, W., Sikora, S., Spady, D., Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig. Dis. Sci. 56:3 (2011), 825–829.
45. Enioutina, E.Y., Bareyan, D., Daynes, R.A., Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties. Vaccine 25:7 (2007), 1236–1249.
46. Fellermann, K., et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am. J. Hum. Genet. 79:3 (2006), 439–448.
47. Ferreira, G.B., et al. 1alpha,25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells: a comparison dose-titration study. J. Steroid Biochem. Mol. Biol. 136 (2013), 160–165.
48. Ferreira, G.B., et al. Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways. Cell Rep. 10:5 (2015), 711–725.
49. Fichera, A., et al. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J. Surg. Res. 142:2 (2007), 239–245.
50. Flodstrom-Tullberg, M., et al. Natural killer cells in human autoimmunity. Curr. Opin. Immunol. 21:6 (2009), 634–640.
51. France, M.M., Turner, J.R., The mucosal barrier at a glance. J. Cell Sci. 130:2 (2017), 307–314.
52. Francescone, R., Hou, V., Grivennikov, S.I., Cytokines, IBD, and colitis-associated cancer. Inflamm. Bowel Dis. 21:2 (2015), 409–418.
53. Franchi, L., Munoz-Planillo, R., Nunez, G., Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13:4 (2012), 325–332.
54. Froicu, M., Cantorna, M.T., Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol., 8, 2007, 5.
55. Froicu, M., et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 17:12 (2003), 2386–2392.
56. Fukumori, S., et al. Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells. Drug Metab. Pharmacokinet. 22:5 (2007), 377–381.
57. Funderburg, N.T., et al. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 140:1 (2013), 87–97.
58. Ganz, T., Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:9 (2003), 710–720.
59. Geremia, A., et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun. Rev. 13:1 (2014), 3–10.
60. Giacomin, P.R., et al. Epithelial-intrinsic IKKalpha expression regulates group 3 innate lymphoid cell responses and antibacterial immunity. J. Exp. Med. 212:10 (2015), 1513–1528.
61. Gilbert, R., et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis. Cancer Causes Control 22:3 (2011), 319–340.
62. Giovannucci, E., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 98:7 (2006), 451–459.
63. Golan, M.A., et al. Transgenic expression of vitamin D receptor in gut epithelial cells ameliorates spontaneous colitis caused by Interleukin-10 deficiency. Dig. Dis. Sci. 60:7 (2015), 1941–1947.
64. Gombart, A.F., Saito, T., Koeffler, H.P., Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics, 10, 2009, 321.
65. Griffin, M.D., et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:12 (2001), 6800–6805.
66. Gupta, R.P., et al. CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J. Bone Min. Res. 19:4 (2004), 680–688.
67. Hampe, J., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39:2 (2007), 207–211.
68. Heikkinen, S., et al. Nuclear hormone 1alpha,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res. 39:21 (2011), 9181–9193.
69. Heilborn, J.D., et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol 120:3 (2003), 379–389.
70. Hewison, M., Vitamin D and the immune system: new perspectives on an old theme. Endocrinol. Metab. Clin. North Am. 39:2 (2010), 365–379 (table of contents).
71. Hewison, M., et al. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol 25:2 (2000), 141–148.
72. Hewison, M., et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 170:11 (2003), 5382–5390.
73. Hlavaty, T., et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J. Gastroenterol. 20:42 (2014), 15787–15796.
74. Holick, M.F., High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 81:3 (2006), 353–373.
75. Holick, M.F., Vitamin D deficiency. N. Engl. J. Med. 357:3 (2007), 266–281.
76. Holick, M.F., Schnoes, H.K., DeLuca, H.F., Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc. Natl. Acad. Sci. U. S. A. 68:4 (1971), 803–804.
77. Hoyer-Hansen, M., Jaattela, M., AMP-activated protein kinase: a universal regulator of autophagy?. Autophagy 3:4 (2007), 381–383.
78. Hughes, P.J., et al. Vitamin D3-driven signals for myeloid cell differentiation–Implications for differentiation therapy. Leukemia Res. 34:5 (2010), 553–565.
79. Hugot, J.P., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:6837 (2001), 599–603.
80. Hummel, D.M., et al. Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesis. J. Steroid Biochem. Mol. Biol. 136 (2013), 284–288.
81. Hypponen, E., Power, C., Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am. J. Clin. Nutr. 85:3 (2007), 860–868.
82. Iliev, I.D., et al. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58:11 (2009), 1481–1489.
83. Imai, Y., et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. U. S. A. 110:34 (2013), 13921–13926.
84. Jahani, R., et al. Low vitamin D status throughout life results in an inflammatory prone status but does not alter bone mineral or strength in healthy 3-month-old CD-1 male mice. Mol. Nutr. Food Res. 58:7 (2014), 1491–1501.
85. Jantchou, P., et al. High residential sun exposure is associated with a low risk of incident Crohn's disease in the prospective E3N cohort. Inflamm. Bowel Dis. 20:1 (2014), 75–81.
86. Jeffery, L.E., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183:9 (2009), 5458–5467.
87. Jeffery, L.E., et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J. Immunol. 189:11 (2012), 5155–5164.
88. Jin, D., et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. Clin. Ther. 37:5 (2015), 996–1009 e7.
89. Jorgensen, S.P., et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 32:3 (2010), 377–383.
90. Juzeniene, A., et al. The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. Int. J. Infect. Dis. 14:12 (2010), e1099–e1105.
91. Juzeniene, A., et al. The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. Int. J. Infect. Dis., 14(12), 2010, e1099 105.
92. Kamei, Y., et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:3 (1996), 403–414.
93. Kawarau, A.T.E., Tanida, N., Nakagawa, K., Yamamoto, H., Sawada, K., Inhibitory effect of lonh term 1 alpha-hydroxyvitamin D3 administration on Helicobacter pylori infection. J. Clin. Biochem. Nutr., 38, 2006, 4.
94. Kelsey, S.M., et al. Gamma interferon augments functional and phenotypic characteristics of vitamin D3-induced monocytoid differentiation in the U937 human leukaemic cell line. Leuk. Res. 14:11–12 (1990), 1027–1033.
95. Khalili, H., et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 61:12 (2012), 1686–1692.
96. Khoo, A.L., et al. 1,25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology 134:4 (2011), 459–468.
97. Khor, B., Gardet, A., Xavier, R.J., Genetics and pathogenesis of inflammatory bowel disease. Nature 474:7351 (2011), 307–317.
98. Kim, B.S., et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med., 5(170), 2013, 170 ra16.
99. Klose, C.S., Artis, D., Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat. Immunol. 17:7 (2016), 765–774.
100. Kong, J., et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 294:1 (2008), G208–G216.
101. Kugelberg, E., Infection: TSLP complements neutrophil killing of bacteria. Nat. Rev. Immunol. 17:1 (2017), 4–5.
102. Kundu, R., et al. Regulation of CYP27B1 and CYP24A1 hydroxylases limits cell-autonomous activation of vitamin D in dendritic cells. Eur. J. Immunol. 44:6 (2014), 1781–1790.
103. Lagishetty, V., et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology 151:6 (2010), 2423–2432.
104. Landheer, J., et al. TSLP is differentially regulated by vitamin D3 and cytokines in human skin. Immun. Inflamm. Dis. 3:1 (2015), 32–43.
105. Larmonier, C.B., et al. High vitamin D3 diet administered during active colitis negatively affects bone metabolism in an adoptive T cell transfer model. Am. J. Physiol. Gastrointest. Liver Physiol. 305:1 (2013), G35–G46.
106. Lawson, D.E., et al. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 230:5291 (1971), 228–230.
107. Leung, S., et al. The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol. Immunol. 7:3 (2010), 182–189.
108. Levin, A.D., et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig. Dis. Sci. 56:3 (2011), 830–836.
109. Li, J., et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum. Mol. Genet. 13:16 (2004), 1715–1725.
110. Li, M., et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc. Natl. Acad. Sci. U. S. A. 103:31 (2006), 11736–11741.
111. Li, B., et al. Targeted 25-hydroxyvitamin D3 1alpha-hydroxylase adoptive gene therapy ameliorates dss-induced colitis without causing hypercalcemia in mice. Mol. Ther. 23:2 (2015), 339–351.
112. Lim, W.C., Hanauer, S.B., Li, Y.C., Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2:7 (2005), 308–315.
113. Lin, R., White, J.H., The pleiotropic actions of vitamin D. Bioessays 26:1 (2004), 21–28.
114. Lin, R., et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16:6 (2002), 1243–1256.
115. Liu, P.T., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:5768 (2006), 1770–1773.
116. Liu, P.T., Krutzik, S.R., Modlin, R.L., Therapeutic implications of the TLR and VDR partnership. Trends Mol. Med. 13:3 (2007), 117–124.
117. Liu, W., et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J. Clin. Invest. 123:9 (2013), 3983–3996.
118. Loftus, E.V. Jr., Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:6 (2004), 1504–1517.
119. Lyakh, L.A., et al. TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J. Immunol. 174:4 (2005), 2061–2070.
120. MacDonald, P.N., et al. Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids 66:3–5 (2001), 171–176.
121. MacDonald, T.T., et al. What's the next best cytokine target in IBD?. Inflamm. Bowel Dis. 18:11 (2012), 2180–2189.
122. Mahon, B.D., et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell Biochem. 89:5 (2003), 922–932.
123. Maloy, K.J., Powrie, F., Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474:7351 (2011), 298–306.
124. Mangoni, M.L., McDermott, A.M., Zasloff, M., Antimicrobial peptides and wound healing: biological and therapeutic considerations. Exp. Dermatol 25:3 (2016), 167–173.
125. Mantovani, A., et al. Cancer-related inflammation. Nature 454:7203 (2008), 436–444.
126. Mapes, B., et al. Ex vivo culture of primary human colonic tissue for studying transcriptional responses to 1alpha,25(OH)2 and 25(OH) vitamin D. Physiol. Genomics 46:8 (2014), 302–308.
127. Marks, D.J., Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity?. Curr. Opin. Gastroenterol. 27:4 (2011), 328–334.
128. Martinet, L., Smyth, M.J., Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15:4 (2015), 243–254.
129. Matthews, D., et al. Genomic vitamin D signaling in breast cancer: insights from animal models and human cells. J. Steroid Biochem. Mol. Biol. 121:1–2 (2010), 362–367.
130. McGovern, D.P., Kugathasan, S., Cho, J.H., Genetics of inflammatory bowel diseases. Gastroenterology 149:5 (2015), 1163–1176 e2.
131. Medzhitov, R., Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:2 (2001), 135–145.
132. Meeker, S., et al. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res. 74:16 (2014), 4398–4408.
133. Meeker, S., et al. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J. Gastroenterol. 22:3 (2016), 933–948.
134. Molodecky, N.A., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:1 (2012), 46–54 e42; quiz e30.
135. Monticelli, L.A., et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12:11 (2011), 1045–1054.
136. Mora, J.R., Iwata, M., von Andrian, U.H., Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 8:9 (2008), 685–698.
137. Munger, K.L., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA J. Am. Med. Assoc. 296:23 (2006), 2832–2838.
138. Murillo, G., et al. Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J. Steroid Biochem. Mol. Biol. 121:1–2 (2010), 403–407.
139. Ooi, J.H., et al. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J. Nutr. 143:10 (2013), 1679–1686.
140. Palmer, H.G., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 154:2 (2001), 369–387.
141. Panda, D.K., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. U. S. A. 98:13 (2001), 7498–7503.
142. Pearce, E.J., Everts, B., Dendritic cell metabolism. Nat. Rev. Immunol. 15:1 (2015), 18–29.
143. Peterson, L.W., Artis, D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14:3 (2014), 141–153.
144. Raftery, T., O'Sullivan, M., Optimal vitamin D levels in Crohn's disease: a review. Proc. Nutr. Soc. 74:1 (2015), 56–66.
145. Raftery, T., et al. Vitamin D status is associated with intestinal inflammation as measured by fecal calprotectin in Crohn's disease in clinical remission. Dig. Dis. Sci. 60:8 (2015), 2427–2435.
146. Raftery, T., et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. United Eur. Gastroenterol. J. 3:3 (2015), 294–302.
147. Ramagopalan, S.V., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 20:10 (2010), 1352–1360.
148. Reche, P.A., et al. Human thymic stromal lymphopoietin preferentially stimulates myeloid cells. J. Immunol. 167:1 (2001), 336–343.
149. Reynolds, I.S., et al. A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer. Int. J. Colorectal Dis. 32:4 (2017), 443–451.
150. Rioux, J.D., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39:5 (2007), 596–604.
151. Rubin, D.C., Shaker, A., Levin, M.S., Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front. Immunol., 3, 2012, 107.
152. Ruiter, B., Patil, S.U., Shreffler, W.G., Vitamins A and D have antagonistic effects on expression of effector cytokines and gut-homing integrin in human innate lymphoid cells. Clin. Exp. Allergy 45:7 (2015), 1214–1225.
153. Ryynanen, J., Carlberg, C., Primary 1,25-dihydroxyvitamin D3 response of the interleukin 8 gene cluster in human monocyte- and macrophage-like cells. PLoS One, 8(10), 2013, e78170.
154. Ryz, N.R., et al. Active vitamin D (1,25-dihydroxyvitamin D3) increases host susceptibility to Citrobacter rodentium by suppressing mucosal Th17 responses. Am. J. Physiol. Gastrointest. Liver Physiol. 303:12 (2012), G1299–G1311.
155. Samson, C.M., et al. Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 55:6 (2012), 679–688.
156. Sawa, S., et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat. Immunol. 12:4 (2011), 320–326.
157. Sawada, N., et al. Structure-function analysis of CYP27B1 and CYP27A1. Studies on mutants from patients with vitamin D-dependent rickets type I (VDDR-I) and cerebrotendinous xanthomatosis (CTX). Eur. J. Biochem. 268:24 (2001), 6607–6615.
158. Schmiedlin-Ren, P., et al. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol. Pharmacol. 51:5 (1997), 741–754.
159. Schroder, K., Tschopp, J., The inflammasomes. Cell 140:6 (2010), 821–832.
160. Shah, S., et al. The molecular basis of vitamin D receptor and β-catenin crossregulation. Mol. Cell 21:6 (2006), 799–809.
161. Sigmundsdottir, H., et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8:3 (2007), 285–293.
162. Smolders, J., et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 194:1–2 (2008), 7–17.
163. Sonnenberg, G.F., et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336:6086 (2012), 1321–1325.
164. Soumelis, V., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3:7 (2002), 673–680.
165. Strauch, U.G., et al. Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulfate-induced colitis by modulation of intestinal dendritic cell numbers and phenotype. World J. Gastroenterol. 13:48 (2007), 6529–6537.
166. Su, D., et al. Vitamin D signaling through induction of Paneth cell defensins maintains gut microbiota and improves metabolic disorders and hepatic steatosis in animal models. Front. Physiol., 7, 2016, 498.
167. Sun, J., VDR/vitamin D receptor regulates autophagic activity through ATG16L1. Autophagy 12:6 (2016), 1057–1058.
168. Takiishi, T., et al. Vitamin D and diabetes. Endocrinol. metabolism Clin. N. Am. 39:2 (2010), 419–446.
169. Tanaka, Y., Deluca, H.F., Role of 1,25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc. Natl. Acad. Sci. U. S. A. 71:4 (1974), 1040–1044.
170. Tavera-Mendoza, L.E., White, J.H., Cell defenses and the sunshine vitamin. Sci. Am. 297:5 (2007), 62–65 68-70, 72.
171. Taylor, B.C., et al. TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J. Exp. Med. 206:3 (2009), 655–667.
172. Theodoropoulos, C., et al. Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin. Endocrinol. (Oxf) 58:4 (2003), 489–499.
173. Thompson, P.D., et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun. 299:5 (2002), 730–738.
174. Townsend, K., et al. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 97:1–2 (2005), 103–109.
175. Travassos, L.H., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11:1 (2010), 55–62.
176. Ulitsky, A., et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J. Parenter. Enter. Nutr. 35:3 (2011), 308–316.
177. Ullman, T.A., Itzkowitz, S.H., Intestinal inflammation and cancer. Gastroenterology 140:6 (2011), 1807–1816.
178. Usui, E., et al. Unique property of liver mitochondrial P450 to catalyze the two physiologically important reactions involved in both cholesterol catabolism and vitamin D activation. FEBS Lett. 274:1–2 (1990), 175–177.
179. Van Brussel, I., et al. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?. Autoimmun. Rev. 13:2 (2014), 138–150.
180. van der Mei, I.A., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Bmj, 327(7410), 2003, 316.
181. Vander Lugt, B., et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat. Immunol. 15:2 (2014), 161–167.
182. Veldman, C.M., Cantorna, M.T., DeLuca, H.F., Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 374:2 (2000), 334–338.
183. Verway, M., et al. Vitamin D induces interleukin-1beta expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog, 9(6), 2013, e1003407.
184. Voss, E., et al. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J. Biol. Chem. 281:4 (2006), 2005–2011.
185. Wada, K., et al. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol. Rep. 22:5 (2009), 1021–1025.
186. Wagner, D., et al. Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. Anticancer Res. 32:1 (2012), 259–263.
187. Waldner, M.J., et al. Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer. Inflamm. Bowel Dis. 16:4 (2010), 559–567.
188. Wang, T.T., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173:5 (2004), 2909–2912.
189. Wang, T.T., et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J. Biol. Chem. 285:4 (2010), 2227–2231.
190. Wang, D., et al. Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer. Proc. Natl. Acad. Sci. U. S. A. 108:25 (2011), 10272–10277.
191. Wang, J., et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat. Genet. 48:11 (2016), 1396–1406.
192. Weeres, M.A., et al. The effects of 1,25-dihydroxyvitamin D3 on in vitro human NK cell development from hematopoietic stem cells. J. Immunol. 193:7 (2014), 3456–3462.
193. White, J.H., Vitamin D metabolism and signaling in the immune system. Rev. Endocr. Metab. Disord. 13:1 (2012), 21–29.
194. White, J.H., Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch. Biochem. Biophys. 523:1 (2012), 58–63.
195. Wolk, K., et al. IL-22 increases the innate immunity of tissues. Immunity 21:2 (2004), 241–254.
196. Wolpowitz, D., Gilchrest, B.A., The vitamin D questions: how much do you need and how should you get it?. J. Am. Acad. Dermatology 54:2 (2006), 301–317.
197. Wu, S., et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut 64:7 (2015), 1082–1094.
198. Yamada, S., Shimizu, M., Yamamoto, K., Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. Med. Res. Rev. 23:1 (2003), 89–115.
199. Yamamoto, H., et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J. Bone Min. Res. 14:2 (1999), 240–247.
200. Yang, C.Y., et al. The implication of vitamin D and autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 45:2 (2013), 217–226.
201. Yang, L., et al. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn's patients. Clin. Transl. Gastroenterol., 4, 2013, e33.
202. Yatsunenko, T., et al. Human gut microbiome viewed across age and geography. Nature 486:7402 (2012), 222–227.
203. Youssef, D., et al. Differences in outcomes between cholecalciferol and ergocalciferol supplementation in veterans with inflammatory bowel disease. Geriatr. Gerontol. Int. 12:3 (2012), 475–480.
204. Yu, S., et al. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc. Natl. Acad. Sci. U. S. A. 105:52 (2008), 20834–20839.
205. Zanello, L.P., Norman, A.W., Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc. Natl. Acad. Sci. U. S. A. 101:6 (2004), 1589–1594.
206. Zator, Z.A., et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-alpha therapy in inflammatory bowel diseases. JPEN J. Parenter. Enter. Nutr. 38:3 (2014), 385–391.
207. Zehnder, D., et al. Extrarenal expression of 25-hydroxyvitamin d3-1α-hydroxylase. J. Clin. Endocrinol. Metabolism 86:2 (2001), 888–894.
208. Zenewicz, L.A., et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29:6 (2008), 947–957.
209. Zhang, J., et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat. Struct. Mol. Biol. 18:5 (2011), 556–563.
210. Zhao, H., et al. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol., 12, 2012, 57.
211. Zheng, Y., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14:3 (2008), 282–289.
212. Zhu, J.G., et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc. Natl. Acad. Sci. U. S. A. 110:39 (2013), 15650–15655.
213. Zhu, T., et al. Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. Int. J. Mol. Med. 35:5 (2015), 1213–1218.